Search Results
Your search for can matches 13758 pages
Showing 3801 - 3850Analysis From the International Germ Cell Cancer Collaborative Group Update Consortium
In an analysis of a modern cohort of patients with metastatic seminoma reported in the Journal of Clinical Oncology, Beyer et al, members of the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium, found that progression-free and overall survival have improved compared...
Older Patients With Multiple Myeloma May Be Able to Avoid Long-Term Steroid Use
The combination of lenalidomide plus the steroid dexamethasone (together called Rd) is considered standard treatment for elderly patients with multiple myeloma. However, prolonged steroid use can be harmful for some older adults. A new study published by Larocca et al in the journal Blood found...
Maintenance Olaparib Yields Strong and Sustained Benefit in Ovarian Cancer
In the 5-year follow-up of the pivotal SOLO-1 trial in women with advanced ovarian cancer and a BRCA1/2 mutation, maintenance treatment with olaparib led to a doubling in progression-free survival. William H. Bradley, MD, presented these findings at the Society of Gynecologic Oncology (SGO) 2021...
Frailty May Impact Surgical Outcomes in Patients With Ovarian Cancer
Frailty may be a better predictor of poor surgical outcomes in patients with ovarian cancer than age, according to two studies reported at the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer. Researchers found that frail patients are less likely to undergo...
Recent Chemotherapy or Immunotherapy for Gynecologic Cancer Does Not Raise Risk of Death Due to COVID-19
Although some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer does not raise the risk of hospitalization or death due to COVID-19. The study results were...
Survey Reveals Workplace Bullying, Gender Discrimination, and Microaggressions Not Uncommon for Women Gynecologic Oncologists
In a survey of 250 female gynecologic oncologists, more than half reported experiencing instances of bullying, gender discrimination, or microaggressions. They also reported that having a female department chair provided no buffer against these forms of gender harassment or discrimination in the...
FDA Pipeline: Priority Review for Kidney Cancer Treatment, Fast Track Designation for NSCLC Treatment
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to the HIF-2α inhibitor belzutifan for the treatment of patients with von Hippel-Lindau (VHL) disease–associated renal cell carcinoma. The agency also granted Fast Track designation to poziotinib for the treatment of...
Can Treatment for Prostate Cancer Affect Smell and Taste?
One in six men being treated for advanced prostate cancer reported experiencing a reduced sense of smell and taste, according to a study published by Alonzi et al in the journal Supportive Care in Cancer. The study authors noted that a reduced sense of smell and taste among some patients with...
Updated Evidence Report and Systematic Review of Low-Dose CT Screening for Lung Cancer
In an analysis of updated evidence on low-dose computed tomography (CT) screening for lung cancer reported in JAMA, Jonas et al found that screening can reduce lung cancer mortality but may be associated with a range of potential harms. The analysis was performed to inform the new U.S. Preventive...
High Tumor Mutational Burden Predicts Immunotherapy Response in Some—but Not All—Cancers
High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology. The findings suggest that TMB status may not be reliably used as a universal...
Is HPV Vaccination for Adults Aged 26 and Older Cost-Effective?
Vaccinating adults aged 26 and older against the human papillomavirus (HPV) may not be cost-effective, according to a new study published by Kim et al in PLOS Medicine. “Our study found that the added health benefit of increasing the vaccination age limit beyond 26 years is minimal, and that the...
Novel HER2-Targeted Therapies Pose Sequencing Challenges
With three new HER2-targeted therapies approved in the past 15 months alone, the treatment landscape for patients with metastatic breast cancer has become increasingly crowded. In the third-line setting and beyond, there are now at least eight HER2-targeted agents approved by the U.S. Food and Drug ...
FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval
Recently, the U.S. Food and Drug Administration (FDA) announced that the agency will hold a public meeting of the Oncologic Drugs Advisory Committee on April 27 to 29 to discuss six indications granted accelerated approval that have since reported results from confirmatory trials that have not...
Expect Questions From Older Breast Cancer Survivors About Discontinuing Routine Surveillance Mammography
Consensus guidelines recommending that routine surveillance mammography be discontinued for older breast cancer survivors with a limited life expectancy1 may raise questions among patients concerned about undetected cancer recurrence. Informing older survivors about the new recommendations and the...
Older Breast Cancer Survivors May Consider Discontinuing Screening Mammography in the Setting of Limited Life Expectancy
Newly issued mammography screening guidelines for breast cancer survivors aged 75 and older recommend discontinuing routine mammography for those with a life expectancy of less than 5 years and considering discontinuation of routine screening for those with a life expectancy between 5 and 10 years. ...
New Survey Reveals Hesitancy Around COVID-19 Vaccination Among Patients With Hematologic Malignancies and Survivors
A survey of more than 6,500 U.S. patients with blood cancer and survivors revealed that only half are very likely to get a COVID-19 vaccine, while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston...
Why Might Night-Shift Workers Have a Higher Risk of Developing Cancer?
New clues as to why night-shift workers are at an increased risk of developing certain types of cancer were uncovered in a new study published by Koritala et al in the Journal of Pineal Research. The study involved a controlled laboratory experiment that used healthy volunteers who were on...
Miami Breast Cancer Conference: Genomic Assays Show Utility in Predicting Pathologic Complete Response Rate in Pre- and Postmenopausal Patients With Breast Cancer
New data from the prospective Neoadjuvant Breast Symphony Trial (NBRST), which demonstrated the predictive and prognostic abilities of the MammaPrint and BluePrint assays and underpinned their preoperative utility in pre-and postmenopausal patients with breast cancer, were presented at PER’s Miami...
Repurposing Available Drugs for COVID-19: An Ongoing Initiative
As of this writing, no drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19, although several have received emergency use authorization and many others are being used off-label during the pandemic. In addition to searching for novel therapies, David...
New Study Finds Muscle Mass and Density Are Correlated With Survival and Outcomes in Patients With Advanced Cancer
New research published by van Seventer et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that muscle mass was correlated with survival, while muscle radiodensity was associated with symptom burden, health-care use, and survival in patients with advanced cancer undergoing ...
ASCO Guideline Update Offers Four Standards of Care for Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
A recent ASCO guideline update, prompted by data from several phase III randomized controlled trials, summarizes the evidence supporting the best initial treatment options for the management of noncastrate advanced, recurrent, or metastatic prostate cancer. The hope is that the guideline will help...
New Research Statement Recommends Streamlining and Standardizing Clinical Trial Site Feasibility Assessments
Feasibility assessments for clinical trials are conducted to establish that prospective trial sites can safely and effectively meet study goals and protocol requirements; however, a new research statement from ASCO asserts that current standards are “costly, inconsistent, inefficient, labor...
ASCO and Friends of Cancer Research Recommend Expanding Patient Access to Cancer Clinical Trials by Further Broadening Eligibility Criteria
ASCO and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients.1 The joint recommendations are detailed in a series of articles...
Neoadjuvant Atezolizumab in Lung Cancer: LCMC3 Trial Meets Primary Endpoint
Neoadjuvant treatment with single-agent atezolizumab in patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and a pathologic complete response rate of 7%, in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study.1 The findings were...
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Honored With Mary J. Matthews Pathology/Translational Research Award
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Director of the CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, has been recognized by the International Association for the Study of Lung Cancer (IASLC) with the Mary J. Matthews Pathology/Translational Research Award. The award ...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess Margaret...
Oncologist Survey Identifies Knowledge Gaps in Cholangiocarcinoma Mutations
In the treatment of cholangiocarcinoma, many clinicians may be unaware of the importance of the major oncogenic mutations and other alterations that can be identified and targeted, according to a survey of oncologists presented at the 2021 Gastrointestinal Cancers Symposium.1 “Recent developments...
Fallout From COVID-19: Decline in Cancer Screening and Increase in Cancer-Related Deaths
Various studies at institutions in the United States and abroad have shown a substantial decline in cancer screening rates during the COVID-19 pandemic, suggesting that fewer cancers will be detected by screening and when they do manifest, they will be at more advanced stages. Indeed,...
Expert Point of View: Rina Hui, MBBS, PhD, and Melina Marmarelis, MD
“It has been a long time coming to see a positive randomized phase III study with a checkpoint inhibitor in relapsed mesothelioma,” said the study’s invited discussant, Rina Hui, MBBS, PhD, Clinical Professor of Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney,...
Kratom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on...
Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive Anaplastic Large Cell Lymphoma
On January 14, 2021, crizotinib was approved for treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.1,2 The safety and efficacy of crizotinib have not been established in older...
Tepotinib for Metastatic NSCLC With MET Exon 14–Skipping Alterations
On February 3, 2021, tepotinib was granted accelerated approval for treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations.1,2 Supporting Efficacy Data Approval was supported by findings from the...
Overcoming Gender Disparity in Evaluating Sexual Health Following a Cancer Diagnosis
The results from a recent study showcase the disturbing prevalence of sexual dysfunction as a treatment side effect of cancer and gender disparity in how the problem is addressed by physicians.1 The study, conducted by James Taylor, MD, MPH, Chief Resident in the Department of Radiation Oncology at ...
The Emerging Role of Exercise in Cancer Prevention and Treatment
The holistic benefits derived from exercise in preventing and ameliorating chronic health conditions such as cardiovascular disease and diabetes are well documented. However, less is known about the salutary effects exercise may have across the cancer setting, especially during treatment....
USPSTF Issues Final Recommendation Statement on Screening for Lung Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for lung cancer in people who do not have signs or symptoms. Based on the evidence, the USPSTF recommends yearly screening using a low-dose computed tomography (CT) scan for people aged...
New Global Breast Cancer Initiative Highlights Renewed Commitment to Improve Survival
A major new collaborative effort, the Global Breast Cancer Initiative, was introduced by the World Health Organization (WHO), with the objective of reducing global breast cancer mortality by 2.5% per year until 2040, thereby averting an estimated 2.5 million deaths. In recognition of International ...
Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin Melanomas
As reported in the Journal of Clinical Oncology, El Sharouni et al have developed nomograms to predict local, regional, and distant recurrence in patients with T1 melanomas. Study Details The study used data from a Dutch population-based cohort of 25,930 patients to develop the nomograms. The...
Expert Point of View: John C. Krauss, MD
Invited discussant John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, said he was impressed by the “rapidity with which the NRG-GI002 trial accrued,” which was about 10 months.1 “Equally...
David Fajgenbaum, MD, MBA, on Repurposing Cancer Drugs to Treat COVID-19
David Fajgenbaum, MD, MBA, of the University of Pennsylvania, talks about his research efforts to find an already-approved drug that could treat his orphan disease—multicentric Castleman disease—and how that methodology may be applied to the coronavirus and the cytokine storm it can cause...
New WHO/IAEA Publication Provides Guidance on Radiotherapy Equipment Procurement
New guidance from the World Health Organization (WHO) and the International Atomic Energy Agency (IAEA) on the procurement of radiotherapy equipment could improve access to this life-saving cancer treatment option across the world. The new technical guidance aims to ensure that the selection of...
Role of Collagen in Pancreatic Cancer Development
Type I collagen produced by cancer-associated fibroblasts may not promote cancer development, but instead, may play a protective role in controlling pancreatic cancer progression. This new understanding supports novel therapeutic approaches that bolster collagen rather than suppress it, according...
Study Identifies Mechanisms Tied to Immunotherapy Resistance Among Patients With Melanoma
Researchers have created a new technique that may help to uncover mechanisms cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments. Investigators tested their new technique with cancer cells and matching immune cells from patients with melanoma...
Study Finds Missing Annual Mammogram Increases Risk of Death From Breast Cancer
Regular mammography screening substantially reduces the risk of dying from breast cancer, according to a large study of over half a million women published by Stephen W. Duffy, MSc, and colleagues in the journal Radiology. Researchers said women who skipped even one scheduled mammography screening...
Bipolar Androgen Therapy vs Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
In the phase II TRANSFORMER trial reported in the Journal of Clinical Oncology, Denmeade et al found no difference in progression-free survival with bipolar androgen therapy—defined as rapid cycling between high and low serum testosterone—vs enzalutamide in men with metastatic castration-resistant...
Study Examines Extrapleural Pneumonectomy After IMRT for Malignant Pleural Mesothelioma
In a Canadian single-center phase II feasibility study reported in The Lancet Oncology, Cho et al found that a treatment protocol (surgery for mesothelioma after radiotherapy, also known as SMART) consisting of hemithoracic intensity-modulated radiotherapy (IMRT) followed by extrapleural...
Anti-CD20 Monoclonal Antibodies and Risk of Severe COVID-19 Infection and Death in Patients With Lymphoma
Patients with lymphoma hospitalized for severe COVID-19 infection were at higher risk for prolonged hospital stay and death if they were treated with B-cell–depleting therapies (eg, rituximab, obinutuzumab) within the previous 12 months. The risk of persistent COVID-19 infection was also higher in...
Machine Learning Algorithm Is Successful in Predicting Malignancy in Patients With Multiple Pulmonary Nodules
Although guidelines exist for the use of several clinical prediction models based on logistic regression to help estimate the risk of lung cancer before treatment decision-making, they almost all focus on solitary pulmonary nodules, and have not shown accuracy in predicting malignancy in multiple...
ASCO’s Road to Recovery Report Outlines Lessons Learned From the COVID-19 Pandemic to Improve Oncology Care
In 2020, ASCO established the Steering Group on Cancer Care Delivery and Research in a Post-Pandemic Environment to evaluate the changes made in oncology care delivery, clinical research, and regulatory oversight in response to the COVID-19 pandemic as well as to make recommendations on how to...
CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma?
At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic clear cell renal cell carcinoma (RCC). The...
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine
On February 27, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third vaccine for the prevention of COVID-19. The EUA allows the Janssen COVID-19 Vaccine to be distributed in the United States for use in individuals 18 years of age and older. The FDA...
